AR050358A1 - Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo - Google Patents

Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo

Info

Publication number
AR050358A1
AR050358A1 ARP050103078A ARP050103078A AR050358A1 AR 050358 A1 AR050358 A1 AR 050358A1 AR P050103078 A ARP050103078 A AR P050103078A AR P050103078 A ARP050103078 A AR P050103078A AR 050358 A1 AR050358 A1 AR 050358A1
Authority
AR
Argentina
Prior art keywords
tetramethylchroman
hydroxy
compositions
piperazine
ethyl
Prior art date
Application number
ARP050103078A
Other languages
English (en)
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of AR050358A1 publication Critical patent/AR050358A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

Se proveen composiciones terapéuticas. Las composiciones incluyen una molécula unica que puede exhibir propiedades secuestrantes y antioxidantes de carbonilo. Esto puede rducir efectivamente la inflamacion, el estrés oxidativo y el estrés de carbonilo, a fin de prevenir y/o tratar la enfermedad cardiovascular y las enfermedades inflamatorias en pacientes con enfermedades renales. Método de preparacion de la composicion; método de tratamiento. Reivindicacion 8: La composicion de la reivindicacion 6, caracterizada porque el derivado de vitamina E se selecciona del grupo que consiste de 2-(6-hidroxi-2,5,7,8-tetrametilcroman-2-il)-1-(aminoxi)etano; N-[2-(6-hidroxi-2,5,7,8-tetrametilcroman-2-il)etil]-N'-(aminoacetil)-piperazina; N- [2-(6-hidroxi-tetrametilcroman-2-il)etil]-N'-(cisteinil)-piperazina; N-[2-(6-hidroxi-tetrametilcroman-2-il)etil]-N'-(penicilamil)-piperazina, derivados de eso, y combinaciones de eso.
ARP050103078A 2004-07-26 2005-07-25 Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo AR050358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/899,194 US7384558B2 (en) 2004-07-26 2004-07-26 Compositions capable of inhibiting reactive oxygen and carbonyl species

Publications (1)

Publication Number Publication Date
AR050358A1 true AR050358A1 (es) 2006-10-18

Family

ID=35134231

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103078A AR050358A1 (es) 2004-07-26 2005-07-25 Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo

Country Status (7)

Country Link
US (1) US7384558B2 (es)
EP (1) EP1771168A1 (es)
JP (1) JP2008507580A (es)
AR (1) AR050358A1 (es)
MX (1) MX2007000742A (es)
TW (1) TW200614986A (es)
WO (1) WO2006019855A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4004523B1 (ja) * 2006-04-21 2007-11-07 株式会社日本トリム 透析液調製用水およびそれを用いた透析液、透析液の製造方法ならびに透析装置
US20080138481A1 (en) * 2006-12-07 2008-06-12 Chi-Tang Ho Methods of reducing reactive carbonyl species
CA2932121A1 (en) * 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
TW201338803A (zh) * 2012-03-23 2013-10-01 zheng-yi Lin 用於治療寵物腎衰竭之醫藥組合物
JP6255975B2 (ja) 2012-12-27 2018-01-10 Jnc株式会社 液晶組成物、酸化防止剤および液晶表示素子
EP3120842A1 (en) 2015-07-20 2017-01-25 Opterion Health AG Peritoneal therapeutic fluid
WO2018181074A1 (ja) * 2017-03-30 2018-10-04 株式会社日本トリム 血液透析用の透析液

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US17995A (en) * 1857-08-11 Winnowing-mill
US119957A (en) * 1871-10-17 Improvement in photographic tents
US37329A (en) * 1863-01-06 Improvement in rammer-connections for revolving fire-arms
US138501A (en) * 1873-05-06 Improvement in molasses-pitchers
US4105A (en) * 1845-07-10 Fait-mill
US65292A (en) * 1867-05-28 Improved apparatus for tanning
US20507A (en) * 1858-06-08 Combined umbrella and head-best
DE3010504A1 (de) * 1980-03-19 1981-10-01 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von 2-hydroxyalkylchromanen
DE3615473A1 (de) * 1986-05-07 1987-11-12 Basf Ag Verfahren zur herstellung von o-substituierten hydroxylaminen
CA2011899A1 (en) 1989-03-13 1990-09-13 Masaaki Toda Benzopyran derivatives
US5266709A (en) * 1989-03-13 1993-11-30 Ono Pharmaceutical Co., Ltd. Benzopyran derivatives
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
JPH04308586A (ja) 1991-04-05 1992-10-30 Ono Pharmaceut Co Ltd ベンゾピラン誘導体
AU667623B2 (en) * 1993-01-19 1996-03-28 Baxter International Inc. Multiple chamber container
US5527272A (en) * 1994-02-14 1996-06-18 Fresenius Usa, Inc. Bacteriocidal dialysis collection bag and method
EP0716607B1 (en) 1994-07-01 2002-08-28 Baxter International Inc. Biochemically balanced peritoneal dialysis solutions
JPH11504316A (ja) * 1995-04-05 1999-04-20 ザ ピコワー インスティテュート フォア メディカル リサーチ 進行性グリコシル化終末産物に結合する薬剤及びその使用方法
JPH08337590A (ja) 1995-06-15 1996-12-24 Terumo Corp 腹膜保護成分およびそれを含有した腹膜透析液
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
ZA978002B (en) * 1996-09-11 1998-03-02 Baxter Int Containers and methods for storing and admixing medical solutions.
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5925542A (en) * 1997-05-05 1999-07-20 Incyte Pharmaceuticals, Inc. Nucleic acid encoding human phosphodiesterase regulatory subunit
JPH1171273A (ja) 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
US6258577B1 (en) * 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
EP2070535B1 (en) * 1998-08-24 2015-07-08 Kurokawa, Kiyoshi Drugs for relieving carbonyl stress and peritoneal dialysates
AU2042200A (en) * 1998-12-07 2000-06-26 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
WO2000051987A2 (en) 1999-03-05 2000-09-08 Kansas University Medical Center Inhibitors of advanced, post-amadori glycosylation reactions
KR100390630B1 (ko) 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
US6309673B1 (en) * 1999-09-10 2001-10-30 Baxter International Inc. Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy
KR20020072557A (ko) * 1999-12-20 2002-09-16 구로카와 기요시 카르보닐 스트레스 개선제
US6417235B2 (en) * 2000-04-14 2002-07-09 University Of Kentucky Research Foundation Method and use of α-amino-β-mercapto-ethane derivatives as dicarbonyl scavengers for treatment of conditions resulting from protein, lipid, and DNA damage
WO2002047677A1 (fr) 2000-12-12 2002-06-20 Tokai University Educational System Agents d'amelioration du stress du a un groupement carbonyle
SE523153C2 (sv) 2000-12-28 2004-03-30 Gambro Lundia Ab Metod för detoxifiering av medicinsk lösning
US7037895B2 (en) 2001-03-27 2006-05-02 Medical College Of Ohio Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
WO2002094179A2 (en) 2001-05-23 2002-11-28 J.B. Chemicals & Pharmaceuticals Ltd. Novel topical microbicidal compositions
US20030065292A1 (en) 2001-06-08 2003-04-03 Darouiche Rabih O. Ozonated medical devices and methods of using ozone to prevent complications from indwelling medical devices
US20030007961A1 (en) * 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
GB0127786D0 (en) 2001-11-20 2002-01-09 Univ Nottingham Impregnation of antimicrobial substances
DE10159245A1 (de) 2001-12-03 2003-06-18 Degussa Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung
US7122210B2 (en) 2002-01-11 2006-10-17 Baxter International Inc. Bicarbonate-based solutions for dialysis therapies
GB0200704D0 (en) 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
US7053059B2 (en) * 2003-07-25 2006-05-30 Baxter International Inc. Dialysis solutions with reduced levels of glucose degradation products

Also Published As

Publication number Publication date
MX2007000742A (es) 2007-03-30
JP2008507580A (ja) 2008-03-13
TW200614986A (en) 2006-05-16
US20060016752A1 (en) 2006-01-26
EP1771168A1 (en) 2007-04-11
US7384558B2 (en) 2008-06-10
WO2006019855A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
AR050358A1 (es) Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo
O'Leary et al. Adaptive plasticity of autophagic proteins to denervation in aging skeletal muscle
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
Vicentini et al. Evaluation of protective effect of a water-in-oil microemulsion incorporating quercetin against UVB-induced damage in hairless mice skin
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
EP2925307A1 (en) Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
NO20060977L (no) Mitokinon-derivater anvendt som mitokondrielle malsokende antioksidanter
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
Ranjbar et al. Cardioprotective effect of resistance training and Crataegus oxyacantha extract on ischemia reperfusion–induced oxidative stress in diabetic rats
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
AR109263A2 (es) Composición que comprende moxidectina
Baranowska-Kuczko et al. Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery
AR042705A1 (es) Derivados de pirazol modulador de ppar
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
EA200702030A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
BRPI0414334A (pt) withanamida isolada e purificada, composto isolado e purificado, método para tratamento de uma doença in vivo em um mamìfero, método para provisão de oxidação em uma composição necessitada da mesma, composição, composição para uso como produto farmacêutico, método para tratamento de uma doença selecionada do grupo que conpreende a doença de alzheimer, obesidade, dores de cabeça de enxaqueca, e depressão, em um paciente, e método para tratamento antioxidante de um mamìfero in vivo
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
BR112022021640A2 (pt) Usos e formulações de canabinoides
ATE424732T1 (de) Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
CA3153877A1 (en) Curcuminoid composition and its therapeutic potential in managing lung fibrosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure